ArticleESMO real world data and digital oncology2026
Automated extraction of temporalized tumor evolution from oncology EMRs using natural language processing.
Article in ESMO real world data and digital oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Extracting temporally sensitive outcomes such as tumor progression from unstructured electronic medical records (EMRs) remains a major challenge in oncology. This study evaluates a solution with a domain-adapted natural language processing (NLP) pipeline designed to extract structured, temporally anchored clinical outcomes from narrative EMR data. Patients and methods: Patients with oncogene-addicted advanced or metastatic non-small-cell lung cancer (NSCLC) treated with oral targeted therapies between January 2020 and June 2023 at a French academic hospital were included. Extracted Facts were benchmarked against expert annotations. All outputs were mapped to Observational Medical Outcome Partnership vocabularies. F1-scores were calculated for the correct Concept detection without and with their Temporality. Real-world progression-free survival (rwPFS) was estimated based on retrieved clinical outcomes. Results: Among 1030 NSCLC patients treated between 2020 and 2023, 112 were confirmed to have advanced or metastatic disease with an oncogenic driver mutation, primarily EGFR ( Conclusions: Our solution demonstrates robust performance for extracting temporally structured tumor outcomes from EMRs and supports the reconstruction of real-world endpoints in oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.